主动脉瓣狭窄（AVS）是一个严重的健康问题，影响着150多万美国人和全球数百万人。梅奥诊所的研究人员正在探索使用一种名为阿塔奎特ataciguat的新药来治疗AVS。发表在《循环》杂志上的临床前和临床研究结果表明，阿替奎特有可能显著减缓疾病进展。确定该药物长期有效性和安全性的最后一步是进行三期试验，与行业合作伙伴一起启动这一关键试验的努力很快就会开始。

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo ...